{
    "doi": "https://doi.org/10.1182/blood-2021-148578",
    "article_title": "CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome ",
    "article_date": "November 5, 2021",
    "session_type": "703.Cellular Immunotherapies: Basic and Translational",
    "abstract_text": "Background: Chimeric Antigen Receptor-modified T cell (CAR-T) therapies have revolutionized cancer immunotherapy, especially in hematological malignancies. Although great results have been achieved during the last years, long-term efficacy is still compromised in some cases and factors behind CAR-T cell disfunction are not fully understood. Recent studies have shown that the control of CAR expression influences CAR-T fitness and antitumoral efficacy 1 . Therefore, we hypothesized that CAR density on the membrane of CAR-T cells could directly affect CAR-T cell function. In this study we perform a functional and genomic analysis of FACS-isolated subpopulations of CAR-T cells with different CAR densities (CAR High and CAR Low ). Methodology: Second generation CAR-T cells with 4-1BB costimulatory domain targeting BCMA were generated by lentiviral transduction of \u03b1CD3/\u03b1CD28 activated T cells that were expanded for 12-14 days in the presence of IL-7/IL-15. Phenotypic analyses were performed by flow cytometry before and after coculture with MM cells. Cytotoxic activity and cytokine production were measured by standard procedures. In vivo antitumoral efficacy was evaluated in xenogeneic tumor models in NSG mice. Transcriptomic (RNA-seq) and epigenetic (ATAC-seq) analysis were performed following stablished protocols 2 . Single cell analysis was performed using the Chromium Single Cell Immune Profiling solution from 10x Genomic that allows simultaneous analysis of gene expression and paired T-cell receptors from a single cell. Gene Regulatory Network (GRN) analysis was performed using SimiC, a novel computational method that infers regulatory dissimilarities 3 . Results: RNA-seq and ATAC-seq analysis revealed completely different profiles between CAR High - and CAR Low -T cells in both CD4 + and CD8 + cell subsets, with >3500 differentially expressed genes (2086 for CD4 + and 1553 for CD8 + ) that were related with increased tonic signaling, T cell activation and proliferation in CAR High -T cells. Functional studies at resting state (before antigen encounter) corroborated that CAR High -T cells presented increased tonic signaling, that lead to a higher basal activation and a more differentiated phenotype with skewed presence of CCR7 + /CD45RA + /CXCR3 + T SCM cells. After antigen-driven activation, increased cytotoxicity and cytokine production was observed in CAR High -T cells, that also presented higher percentage of terminally differentiated effector cells (CCR7 - /CD45RA + ), along with increased exhaustion (PD1 + /LAG3 + /TIGIT + ). This effect was also observed in the infusion products of CARTBCMA-HCB-01 clinical trial for patients with R/R MM (NCT04309981), where products enriched in CAR High -T cells presented increased cytotoxic activity. Although no significant differences were observed in the antitumoral efficacy in vivo , CAR Low -T cells presented increased persistence, suggesting that higher CAR levels could reduce long-term efficacy. Further characterization of CAR-T cells at single cell level (scRNA-seq) showed enrichment of CAR High -T cells in activated CD4 + and exhausted CD8 + cell clusters. The analysis of regulatory dissimilarities driven by different CAR densities with SimiC revealed an increased activity of the regulon associated to NR4A1 transcription factor (a well-known TF driving T cell exhaustion 4 ) in CAR High -T cells, providing mechanistic insights of the regulatory networks behind differential functionality of CAR High -T cells. Finally, to evaluate the impact of CAR density in the clinical outcome of CAR-T therapies, we developed a gene signature associated to increased CAR density, that was applied to transcriptomic data available from public studies 5 . We score the infusion products of several clinical trials testing CTL019 (NCT01029366, NCT01747486 and NCT02640209) and we observed an enrichment on CAR High signature in the products from non-responder patients. Conclusions: Our data demonstrate that CAR density on the membrane of engineered T cells plays important roles in CAR-T activity with a significant impact on clinical outcome. Moreover, the comprehension of regulatory mechanisms driven by CAR densities at the single cell level offer an important tool for the identification of key regulatory factors that could be modulated for the development of improved therapies. Figure 1 View large Download slide Figure 1 View large Download slide  Close modal Disclosures Rodr\u00edguez-Otero:  Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and other expenses. Paiva:  Bristol-Myers Squibb-Celgene, Janssen, and Sanofi: Consultancy; Adaptive, Amgen, Bristol-Myers Squibb-Celgene, Janssen, Kite Pharma, Sanofi and Takeda: Honoraria; Celgene, EngMab, Roche, Sanofi, Takeda: Research Funding. San-Miguel:  AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, Takeda: Consultancy, Other: Advisory board. Pr\u00f3sper:  Oryzon: Honoraria; Janssen: Honoraria; BMS-Celgene: Honoraria, Research Funding.",
    "author_names": [
        "Paula Rodriguez-Marquez",
        "Maria Erendira Calleja-Cervantes",
        "Guillermo Serrano",
        "Maria Luisa Palacios-Berraquero",
        "Diego Alignani",
        "Patxi San Martin-Uriz",
        "Amaia Vilas-Zornoza",
        "Candela Ceballos",
        "Angel Martin-Mallo",
        "Saray Rodr\u00edguez-Diaz",
        "Rebeca Mart\u00ednez-Turrillas",
        "Patricia Jauregui",
        "Cristina Calvi\u00f1o",
        "Susana Inog\u00e9s",
        "Ascensi\u00f3n L\u00f3pez-Diaz de Cerio",
        "Aina Oliver-Cald\u00e9s",
        "Marta Espa\u00f1ol-Rego",
        "Mariona Pascal",
        "Beatriz Martin-Antonio",
        "Manel Juan",
        "\u00c1lvaro Urbano-Ispizua",
        "Carlos Fern\u00e1ndez De Larrea",
        "Maria Cruz Viguria",
        "Ana Margarita Redondo",
        "Paula Rodr\u00edguez-Otero",
        "Jose J. Rifon Roca",
        "Ana Alfonso Pierola",
        "Juan Jose Lasarte",
        "Teresa Lozano",
        "Bruno Paiva",
        "Jes\u00fas F. San-Miguel",
        "Mikel Hern\u00e1ez",
        "Juan Roberto Rodriguez-Madoz",
        "Felipe Pr\u00f3sper"
    ],
    "author_dict_list": [
        {
            "author_name": "Paula Rodriguez-Marquez",
            "author_affiliations": [
                "Hemato-Oncology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Maria Erendira Calleja-Cervantes",
            "author_affiliations": [
                "Hemato-Oncology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Computational Biology Program, CIMA Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Guillermo Serrano",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Computational Biology Program, CIMA Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Luisa Palacios-Berraquero",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Hematology and Hemotherapy Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Diego Alignani",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Flow Cytometry Core, CIMA Universidad de Navarra, Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Patxi San Martin-Uriz",
            "author_affiliations": [
                "Hemato-Oncology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Amaia Vilas-Zornoza",
            "author_affiliations": [
                "Hemato-Oncology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Candela Ceballos",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Hematology Service, Complejo Hospitalario de Navarra, Pamplona, Spain"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Angel Martin-Mallo",
            "author_affiliations": [
                "Hemato-Oncology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Saray Rodr\u00edguez-Diaz",
            "author_affiliations": [
                "Hemato-Oncology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rebeca Mart\u00ednez-Turrillas",
            "author_affiliations": [
                "Hemato-Oncology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Patricia Jauregui",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Cell Therapy Area, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Cristina Calvi\u00f1o",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Cell Therapy Area, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Susana Inog\u00e9s",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain",
                "Cell Therapy Area, Cl\u00ednica Universidad de Navarra, Pamplona, Spain",
                "Immunology and Immunotherapy Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ascensi\u00f3n L\u00f3pez-Diaz de Cerio",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain",
                "Cell Therapy Area, Cl\u00ednica Universidad de Navarra, Pamplona, Spain",
                "Immunology and Immunotherapy Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Aina Oliver-Cald\u00e9s",
            "author_affiliations": [
                "Department of Hematology, IDIBAPS, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marta Espa\u00f1ol-Rego",
            "author_affiliations": [
                "Department of Immunology, IDIBAPS, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mariona Pascal",
            "author_affiliations": [
                "Department of Immunology, IDIBAPS, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Beatriz Martin-Antonio",
            "author_affiliations": [
                "Department of Hematology, IDIBAPS, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Manel Juan",
            "author_affiliations": [
                "Department of Immunology, IDIBAPS, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "\u00c1lvaro Urbano-Ispizua",
            "author_affiliations": [
                "Department of Hematology, IDIBAPS, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carlos Fern\u00e1ndez De Larrea",
            "author_affiliations": [
                "Department of Hematology, IDIBAPS, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Cruz Viguria",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Hematology Service, Complejo Hospitalario de Navarra, Pamplona, Spain"
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ana Margarita Redondo",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Hematology Service, Complejo Hospitalario de Navarra, Pamplona, Spain"
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paula Rodr\u00edguez-Otero",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Hematology and Hemotherapy Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jose J. Rifon Roca",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Hematology and Hemotherapy Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain",
                "Cell Therapy Area, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ana Alfonso Pierola",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Hematology and Hemotherapy Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"
            ],
            "author_rank": 27,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Jose Lasarte",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Immunology and Immunotherapy Program, CIMA Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 28,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Teresa Lozano",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Immunology and Immunotherapy Program, CIMA Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 29,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Bruno Paiva",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Hematology and Hemotherapy Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain",
                "Flow Cytometry Core, CIMA Universidad de Navarra, Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"
            ],
            "author_rank": 30,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jes\u00fas F. San-Miguel",
            "author_affiliations": [
                "Hemato-Oncology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Hematology and Hemotherapy Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"
            ],
            "author_rank": 31,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mikel Hern\u00e1ez",
            "author_affiliations": [
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Computational Biology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"
            ],
            "author_rank": 32,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Roberto Rodriguez-Madoz",
            "author_affiliations": [
                "Hemato-Oncology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"
            ],
            "author_rank": 33,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Felipe Pr\u00f3sper",
            "author_affiliations": [
                "Hemato-Oncology Program, CIMA Universidad de Navarra, Pamplona, Spain",
                "Navarra Institute for Health Research (IdiSNA), Pamplona, Spain",
                "Hematology and Hemotherapy Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain",
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain",
                "Cell Therapy Area, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
            ],
            "author_rank": 34,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-22T15:38:16",
    "is_scraped": "1"
}